Global CAR T Cell Therapy Market, by Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), by Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2.26 Billion in 2022 and is expected to exhibit a CAGR of 20.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing adoption of inorganic strategies such as agreement by the key players in the market is expected to drive the market growth over the forecast period. For instance, in March 2020, Oxford Biomedica, a cell and gene therapy company, signed an agreement with Juno Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company for LentiVector Platform for CAR-T and TCR-T Therapeutics. Under this agreement, Oxford Biomedica will receive payment of US$ 10 million from process development and relating to the GMP manufacture of lentiviral vectors for use in clinical trials.
Global CAR T Cell Therapy Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a significant impact on the CAR T cell therapy market, owing to diminished T-cell response and persistent positive results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on repeat nasopharyngeal swab polymerase chain reaction testing in patient undergone through chimeric antigen receptor T-cell (CAR-T) therapy. For instance, in March 2021, an article was published by JAMA Network, an open access medical journal published by the American Medical Association, according to which patient undergone through chimeric antigen receptor T-cell (CAR-T) therapy and infected with COVID-19 has reduced T-cell response and almost non-existent antibody response despite of receiving convalescent plasma and the antiviral remdesivir. While, the patients nasopharyngeal swab polymerase chain reaction testing shows persistent positive results repetitively.
Global CAR T Cell Therapy Market: Key Developments
In December 2021, Novartis AG, one of the global healthcare company, introduced T-Charge next-generation CAR-T platform which serve as the foundation for various new investigational CAR-T cell therapies at American Society of Hematology Annual Meeting & Exposition (ASH) 2021.
In May 2022, researchers of Stanford University, one of the leading world's leading research and teaching institutions has developed modified CAR-T cell therapy called as SNIP CAR-T which are activated with an oral medication or hepatitis that’s already approved for use in humans
Browse 32 Market Data Tables and 24 Figures spread through 180 Pages and in-depth TOC on “Global CAR T Cell Therapy Market”- Forecast to 2030, Global CAR T Cell Therapy Market, by Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), by Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102
Moreover, increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, in September 2020, data provided by National Cancer Institute, a federal government's principal agency for cancer research and training, according to which in 2020 approximately 1,806,590 cases are diagnosed with cancer and the most common cancer includes breast cancer, non-hodgkin lymphoma, leukemia and etc, globally.
Key Takeaways of the Global CAR T cell therapy Market:
- The global CAR T cell therapy market is expected to exhibit a CAGR of 20.9 % during the forecast period due to the increasing adoption of strategies such as obtaining Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration. For instance, in January 2022, CARsgenTherapeutics Co., Ltd, one of the leading biopharmaceutical company focused on innovative CAR T-cell therapies, obtained the RMAT designation by the U.S. FDA for CT041 CAR T cell therapy for the advanced gastric claudin 18.2 positive tumor.
- Among therapeutic application, acute lymphocytic leukemia segment is estimated to hold a dominant position in the global CAR T cell therapy market over the forecast period, owing to the increasing prevalence of acute lymphocytic leukemia. For instance, in January 2022, data provided by The American Cancer Society, nationwide voluntary health organization, according to which, around 6,660 new cases of acute lymphocytic leukemia were diagnosed from which 3,740 and 2,920 were males and females respectively in United States.
- Among regions, North America is estimated to account for the largest market share in the global CAR T cell therapy market over the forecast period, owing to expansion of strategic alliance by the key players is expected to drive the market growth over the forecast period. For instance, in February 2022, Bristol-Myers Squibb Company, an American multinational pharmaceutical company, announced the strategic alliance with Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, for development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs.
- Major players operating in the global CAR T cell therapy market include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
